Skip to main content

Bruker Value Stock - Dividend - Research Selection

Bruker

ISIN: US1167941087 , WKN: 813534

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, and defect-detection equipment for semiconductor process control, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments and spark optical emission spectroscopy systems. In addition, it offers superconducting and non-superconducting materials and devices. The company serves pharmaceutical, biotechnology and diagnostics, chemical, food and beverage, clinical, polymer, nanotechnology, semiconductor, and industrial companies; nonprofit laboratories; contract research organizations, academic institutions, medical schools, nonprofit or for-profit forensics, agriculture, food and beverage safety, environmental and clinical microbiology laboratories, hospitals, and government departments and agencies; and raw material manufacturers, and other businesses involved in materials analysis. It markets its products through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was founded in 1991 and is headquartered in Billerica, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Bruker, 10x Genomics, PacBio, ICU Medical, and Dentsply Sirona Shares Skyrocket, What You Need To Know

2025-11-21
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

What Recent Analyst Upgrades and Guidance Changes Mean for Bruker’s Evolving Story

2025-11-21
Bruker stock has recently seen its fair value remain steady at $47.82 per share. Its discount rate edged up slightly from 8.33% to 8.45%. Alongside this, forecasts for revenue growth and net profit margin have shifted, with both metrics showing improvement in the latest analysis. Investors and market watchers should stay tuned to learn how to track future developments as analyst sentiment and company fundamentals continue to evolve. Analyst Price Targets don't always capture the full story...

Bruker Stock Earns Relative Strength Rating Upgrade

2025-11-20
Bruker stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 68 to 72.   Can You Really Time The Stock Market? This proprietary rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.

Here Are Thursday’s Top Wall Street Analyst Research Calls: AON, Apollo Global, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA, and More

2025-11-20
Pre-Market Stock Futures: The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA) blew out its fiscal third-quarter results and offered strong forward guidance, though perhaps not as robust as Wall Street had hoped. Shares were up over 5% after the company reported earnings per share of $1.30, above estimates of $1.25, and revenue of ... Here Are Thursday’s Top Wall Street Analyst Research Calls: AON, Apollo Global, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA, and More

Spatial Biology Market Analysis and Forecast, 2025-2035: Stellaromics, RareCyte, and 10x Genomics Drive Innovation and Funding Momentum

2025-11-20
Spatial biology, a rapidly advancing field, delves into the organization and interaction of cells, molecules, and biological processes within native tissue environments. By integrating cutting-edge techniques like spatial transcriptomics, proteomics, metabolomics, and multi-omics with advanced imaging, it provides unparalleled insights into gene, protein, and analyte activity across tissues. As a result, spatial biology is crucial in understanding cellular function, communication, and disease pr

3 Volatile Stocks with Questionable Fundamentals

2025-11-19
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.

3 Healthcare Stocks We Approach with Caution

2025-11-18
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 7.5% has lagged the S&P 500’s 13% climb.

Q3 2025 Portfolio: Focusing On Resilience, Attractive Valuation And Sound Capital Allocation

2025-11-10
The London Company reviews Q3 2025 performance, highlighting AI-driven gains, sector headwinds, and new trades. Explore resilient picks and strategic shifts now.

3 Stocks Under $50 with Warning Signs

2025-11-06
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

Where Does Bruker Stand After Recent Advances in Scientific Instrumentation?

2025-11-05
Ever wondered whether Bruker is poised for a turnaround, or if you’d be getting more value looking elsewhere? If you’re curious about where value may be found in today’s market, this is a helpful place to start. Over the past week, Bruker's stock increased 7.0%, while the last month brought a 10.8% rise, suggesting renewed optimism despite a year-to-date drop of over 31%. Recent headlines have highlighted Bruker’s advancements in scientific instrumentation and partnerships in biotech,...